Q2 2020

Filed Sep 18, 2020 · 10-Q · 80 days after period end · 0001140361-20-020884

Q2 2020 · 10-Q

Revenue—

Net Income

-$3.36M

no prior Q2 2019 on file

EPS Diluted

$0.00

no prior Q2 2019 on file

Operating Cash Flow$0—

Same quarter

no prior Q2 2019 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

ended Jun 30, 2020 · filed Sep 18, 2020 · 80 d after period end

Nautilus Biotechnology, Inc. · CIK 1808805 · Engraved from SEC EDGAR